Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)Paclitaxel (2)Doxorubicin.

Slides:

Advertisements

Similar presentations

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

Advertisements

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Phase Difference = Phase Difference = 0.05.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Figure Figure 18-1 part 1 Figure 18-1 part 2.

1 times table 2 times table 3 times table 4 times table 5 times table

The Cell Division Cycle

Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS > CTPX > SBX6, >

Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were.

 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):

PatientVPA final dose (mg/kg/day) VPA final serum level (mM)(mg/L) Supplemental.

Introduction The following procedure is for the reconstitution of aldoxorubicin drug product for use in the ALDOXORUBICIN-P3-STS-01 study. The reconstitution.

Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.

Supplementary Figure 1. Suzuki et al. DAPI/BrdU BrdU 24 hrs 48 hrs 72 hrs.

AntibodyCatalog #Company Desminab15200Abcam Smooth muscle actinab5694Abcam S100ab868Abcam Cytokeration(AE1/AE3)ab961Abcam P53sc-6243Santa Cruz Calponinab46794Abcam.

Table S1. HTS positive hits.. Figure S1. Isogenic bortezomib (Btz) resistant mouse and human cell models. The indicated human (MM.1S and U266) and mouse.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Tables Learning Support

Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)

A B PC9 PC9/gef B4 Supplementary Figure S1

Mitosis lab Onion Root Tip Mitosis. 1. What type of cells are these? 2. How do you know? 3.What phase of the cell cycle are most cells likely to be in?

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Supplementary Table 5. The R and P values of Spearman’s analysis among the Ki67+ frequency within the total CD8+T cells from different compartments R values.

Supplementary Table 4. The P and P values of Spearman’s analysis among the CM9 tetramer+ frequency within the total CD8+T cells from different compartments.

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Supplementary Figure 1 Sensitive Resistant Cell Count Propidium Iodide

Supplementary figures

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Copyright © 2009 American Medical Association. All rights reserved.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Figures & Tables from the textbook.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Angiogenesis Inhibitors

A B Supplementary Figure 3

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

A B MCF7-ERaWT MCF7-ERaY537S MCF7-ERaY537N MCF7-ERaY537C MCF7-ERaD538G

Definition of the Variables Affecting Efficacy of Immunodepletion Ex Vivo of Peripheral Blood Progenitor Cell Grafts by Alemtuzumab (Campath in the Bag)

a b MCF-7 TR2 MCF-7 TR2 (Fold change) MTT Assay , (Fold change)

Supplementary Figure S2

New Paradigms in HR-Positive Advanced Breast Cancer

Flavonoid DAPI Mitotracker

Volume 51, Issue 6, Pages (September 2013)

Volume 9, Issue 6, Pages (December 2017)

Nicholas D. James, Jim W. Growcott European Urology Supplements

Abemaciclib (µM) LY (µM)

Supplementary Figure 1 ** ** _ _ + + a. b. ** ** _ _ + + c. n=3 RU486

Figure Overview.

Chen Liu, Steven M Reppert Neuron

Figure Overview.

Reh cells, 24 hours c-Myc Ac-p53 b-actin

Leto et al., Supplementary Figure S3

A B Supplementary Figure S1 PC3 cells Vehicle 3β-Adiol

Palbociclib increases proteasome activity and the clearance of protein aggregates without significant effects on autophagy Palbociclib increases proteasome.

Mutant Alanine Position

Name that bone....

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

Supplementary Figure 1 SK-N-SH Vehicle GW9662 Number of cells

Volume 24, Issue 8, Pages (August 2016)

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon cancer cells. Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon.

Sean P. Cullen, Conor J. Kearney, Danielle M. Clancy, Seamus J. Martin

P53-expressing tumor cells circumvent mitosis, express markers consistent with a G1-like state, and become senescent in response to continuous chemotherapeutic.

Supplementary Material

Complete Vehicle Systems.

Presentation transcript:

Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin (3)*Fulvestrant (4)* Clinical Dose125 mg175 mg/m260 mg/m2500 mg/5ml Cmax202 nM0.43 µM1.16 µM46 nM Cave calculation144 nM0.078 µM0.25 µM30 nM based on AUC(AUC 0-24hr 1982 ng.h/ml)(AUC 0-120hr 7993ng.h/ml)(AUC 0-24hr 358ng.h/ml)(AUC 0-15day ng.hr/ml) * Numbers in parenthesis indicate reference number.

Supplementary Table S2. Cell cycle analysis in human bone marrow mononuclear cells treated with palbociclib for 4 days. Dead CellG1 PhaseS PhaseG2/M Phase Vehicle6.25% (± 0.59%)53.96% (± 2.33%)27.93% (± 0.98%)11.75% (± 1.91%) Palbociclib 0.1uM4.32% (± 0.84%)60.98% (± 3.32%)20.61% (± 0.84%)13.19% (± 1.72%) Palbociclib 0.3uM4.66% (± 0.14%)67.4% (± 2.04%)16.10% (± 1.49%)7.04% (± 0.39%) Palbociclib 1uM4.68% (± 1.17%)79.23% (± 1.17%)9.99% (± 2.59%)4.55% (± 0.73%)

Supplementary Figure S1 AB

Supplementary Figure S2

Supplementary Figure S3 **

Supplementary Figure S4